Read our recent announcements about our company, our research, and partnerships.
BlinkLab receives R&D Tax Incentive Refund relating to its U.S. Pilot Study and Australian clinical research initatives
BlinkLab Dx 1 achieved 83.7% sensitivity and 84.7% specificity in a clinically diverse pediatric population, confirming robust real-world diagnostic performance.
BlinkLab is thrilled to share the successful outcome of its Pre-Submission meeting with the FDA, marking a critical step toward achieving 510(k) clearance for its innovative autism diagnostic app, BlinkLab Dx 1. With the study design and data requirements now confirmed, BlinkLab is poised to initiate a robust clinical program that will pave the way for regulatory approval and market entry in the US.
BlinkLab showcases smartphone-mediated neurobehavioral testing as a digital biomarker at Neuroscience 2022.
Sam Wang highlights the science and vision behind BlinkLab’s neurobehavioral tools at Princeton’s innovation showcase.
A major step we are proud to share!
BlinkLab closes seed round!
At Engage 2021, BlinkLab unveils smartphone-based tools for remotely detecting neurodevelopmental disorders like autism and schizophrenia.
Princeton’s BlinkLab technology has earned support from the university’s IP Accelerator Fund to advance its development. This funding helps transform promising discoveries into market-ready innovations through prototyping and performance validation.
Let's make developmental diagnostic evaluation more efficient and accessible.
Stay up to date with BlinkLab's latest news and developments!
You will receive our newsletter. You can opt out via the newsletter.
